These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 16181302)

  • 1. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
    Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
    Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
    Gerson LB; Shetler K; Triadafilopoulos G
    Dig Liver Dis; 2005 Sep; 37(9):651-8. PubMed ID: 15919250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor.
    Fass R; Sampliner RE; Malagon IB; Hayden CW; Camargo L; Wendel CS; Garewal HS
    Aliment Pharmacol Ther; 2000 May; 14(5):597-602. PubMed ID: 10792123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
    Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
    Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
    Srinivasan R; Katz PO; Ramakrishnan A; Katzka DA; Vela MF; Castell DO
    Aliment Pharmacol Ther; 2001 Apr; 15(4):519-24. PubMed ID: 11284781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy.
    Frazzoni M; Savarino E; Manno M; Melotti G; Mirante VG; Mussetto A; Bertani H; Manta R; Conigliaro R
    Aliment Pharmacol Ther; 2009 Sep; 30(5):508-15. PubMed ID: 19519732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
    Todd JA; Basu KK; de Caestecker JS
    Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy.
    Gerson LB; Mitra S; Bleker WF; Yeung P
    Aliment Pharmacol Ther; 2012 Apr; 35(7):803-9. PubMed ID: 22356659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
    Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
    de Bortoli N; Martinucci I; Piaggi P; Maltinti S; Bianchi G; Ciancia E; Gambaccini D; Lenzi F; Costa F; Leonardi G; Ricchiuti A; Mumolo MG; Bellini M; Blandizzi C; Marchi S
    Aliment Pharmacol Ther; 2011 May; 33(9):1019-27. PubMed ID: 21385192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
    Basu KK; Bale R; West KP; de Caestecker JS
    Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
    Sharma P; Sampliner RE; Camargo E
    Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
    Menges M; Müller M; Zeitz M
    Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
    Ouatu-Lascar R; Triadafilopoulos G
    Am J Gastroenterol; 1998 May; 93(5):711-6. PubMed ID: 9625114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
    Cooper BT; Chapman W; Neumann CS; Gearty JC
    Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.
    Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Gut; 1999 Oct; 45(4):489-94. PubMed ID: 10486353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus.
    Lundell L
    Digestion; 1992; 51 Suppl 1():49-58. PubMed ID: 1356869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.
    Marshall RE; Anggiansah A; Manifold DK; Owen WA; Owen WJ
    Gut; 1998 Nov; 43(5):603-6. PubMed ID: 9824338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.